Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Hepatitis C presents increased risk of metabolic syndrome

03 Oct 2018

It appears that the risk of metabolic syndrome (MetS) is heightened in the presence of hepatitis C virus (HCV) infection but is reduced only in lean patients with hepatitis B virus (HBV) infection, a study has found.

The study included 180,359 individuals aged 40 years who underwent a series of community‐based health screenings. Of these, 18,726 (10.4 percent) had HBV, 13,428 (7.4 percent) had HCV and 1,337 (0.7 percent) had HBV plus HCV (B+C). The remaining 146,868 (81.5 percent) were non‐HBV/non‐HCV controls (NBNC).

MetS had a prevalence rate of 30.1 percent overall. For the subgroups, prevalence rates were 25.2 percent in patients with HBV, 31.5 percent in those with HCV, 28.9 percent in those with B+C and 30.7 percent in NBNC controls (p<0.001).

Among 54,361 individuals with MetS, body mass index status was lean in 18.8 percent, overweight in 35.4 percent and obese in 45.8 percent. Compared with obese individuals with MetS, their lean counterparts were older, had more diabetes and had higher metabolic component levels, but had lower alanine transaminase and aspartate transaminase‐platelet ratio index levels.

Logistic regression analysis showed a significant, positive association between HCV infection and MetS (p<0.001). On the other hand, HBV infection was inversely associated with MetS only among lean individuals (p=0.002) but not among the general population.

Researchers pointed out that older age and female gender are the two most important factors contributing to an increased risk of MetS, which is highly prevalent in postmenopausal women.

Additionally, the current study demonstrates that lean MetS, similar to lean nonalcoholic fatty liver disease, may exhibit more manifestations of extrahepatic diseases but not increase the risk of hepatic severity compared with obese MetS, they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.